Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

(2014) Boglarka Gyurkocza et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation

(2014) F Baron et al.   BONE MARROW TRANSPLANTATION

Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease

(2013) Raynier Devillier et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients

(2013) Craig S. Sauter et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

(2013) E. A. Copelan et al.   BLOOD

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation

(2013) C. Bredeson et al.   BLOOD

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

(2013) Rainer Storb et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2013) Arnon Nagler et al.   JOURNAL OF CLINICAL ONCOLOGY

Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT

(2012) Patrice Chevallier et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine

(2012) Je-Hwan Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation

(2011) Koen van Besien et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

(2011) R. J. Soiffer et al.   BLOOD

Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR

(2011) U Popat et al.   BONE MARROW TRANSPLANTATION

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia

(2011) R. Ram et al.   HAEMATOLOGICA

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

(2011) Mohamed L. Sorror et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review

(2011) A Kumar et al.   LEUKEMIA

Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

(2010) Eneida R. Nemecek et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Who is fit for allogeneic transplantation?

(2010) H. J. Deeg et al.   BLOOD

Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies

(2009) Mehdi Hamadani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Defining the Intensity of Conditioning Regimens: Working Definitions

(2009) Andrea Bacigalupo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research

(2009) Sergio Giralt et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

(2009) J. M. Pagel et al.   BLOOD

Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease

(2009) A. B. Pillai et al.   BLOOD

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

(2008) I. F. Khouri et al.   BLOOD

Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro

(2008) X. Feng et al.   BLOOD

Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma

(2007) Amrita Krishnan et al.   JOURNAL OF CLINICAL ONCOLOGY